Glaukos Corporation (GKOS)
Health Care ยท Surgical & Medical Instruments & Apparatus
Glaukos Corporation (GKOS) is listed on the New York Stock Exchange, where its shares have traded since June 25, 2015. SentiSense covers Glaukos Corporation in the Health Care sector, and its Standard Industrial Classification is Surgical & Medical Instruments & Apparatus. Thomas Burns is its chief executive officer. The company reports 1,094 employees, and its corporate website is www.glaukos.com.
About Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Latest reported results
Glaukos Corporation reported revenue of $211.0 million for Q3 FY2026, up 58.0% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 356 institutions reported holding GKOS, with 60.7 million shares worth $8.4 billion in aggregate. The largest reported holders were BlackRock, Vanguard and Janus Henderson (Jupiter Topco). Of the 5 largest reported holders, 3 added shares and 2 reduced their positions during the quarter.
More on GKOS
- GKOS sentiment: whether news and social coverage of Glaukos Corporation leans bullish or bearish, and the stories driving it.
- GKOS ownership: all 356 reporting institutions, plus insider and congressional trades.
- GKOS financials: revenue, net income, operating margin and free cash flow through Q3 FY2026.
Frequently asked questions
What does Glaukos Corporation do?
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases.
What sector is GKOS in?
SentiSense classifies Glaukos Corporation in the Health Care sector, and its Standard Industrial Classification is Surgical & Medical Instruments & Apparatus.
Where does GKOS stock trade?
Glaukos Corporation (GKOS) is listed on the New York Stock Exchange, where its shares have traded since June 25, 2015.
Who is the CEO of Glaukos Corporation?
Thomas Burns is the chief executive officer of Glaukos Corporation.